August 2025 delivered critical clinical practice updates for GLP-1 therapy, including the first generic weight loss approval (Teva’s Saxenda), FDA expansion of Wegovy for liver disease treatment, and major oral formulation breakthroughs from Eli Lilly and Viking Therapeutics. These evidence-based developments provide healthcare providers with new treatment options, expanded patient populations, and enhanced safety protocols that directly impact clinical decision-making.

For GLP‑1 weight loss providers, the latest research, reimbursement changes, and pipeline drugs are redefining how you support patients. This roundup offers concise guidance on preserving lean mass, improving adherence, navigating coverage, and preparing for next‑generation therapies.

GLP-1 trends in June 2025 are redefining obesity treatment—but real-world data reveals more than half of patients quit within a year. This article explores why, what’s coming next, and how providers can adapt to a rapidly changing landscape.

Botox patient satisfaction now defines success in modern aesthetic practice. This guide shows new injectors how to capture feedback, build trust, and grow their business.